- Moxifloxacin population pharmacokinetics in patients with pulmonary tuberculosis and the effect of intermittent high-dose rifapentine.
Moxifloxacin population pharmacokinetics in patients with pulmonary tuberculosis and the effect of intermittent high-dose rifapentine.
Antimicrobial agents and chemotherapy (2012-05-16)
Simbarashe P Zvada, Paolo Denti, Hennie Geldenhuys, Sandra Meredith, Danelle van As, Mark Hatherill, Willem Hanekom, Lubbe Wiesner, Ulrika S H Simonsson, Amina Jindani, Thomas Harrison, Helen M McIlleron
PMID22585223
RESUMEN
We described the population pharmacokinetics of moxifloxacin and the effect of high-dose intermittent rifapentine in patients with pulmonary tuberculosis who were randomized to a continuation-phase regimen of 400 mg moxifloxacin and 900 mg rifapentine twice weekly or 400 mg moxifloxacin and 1,200 mg rifapentine once weekly. A two-compartment model with transit absorption best described moxifloxacin pharmacokinetics. Although rifapentine increased the clearance of moxifloxacin by 8% during antituberculosis treatment compared to that after treatment completion without rifapentine, it did not result in a clinically significant change in moxifloxacin exposure.
MATERIALES